Testing a new drug for B-cell lymphoma that has come back
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell non-Hodgkin lymphoma, such as follicular, marginal zone, mantle cell, or diffuse large B-cell lymphoma.
- Your cancer is measurable on scans and needs treatment now.
- You have already tried at least 2 previous cancer treatments and cannot get standard therapy anymore.
- You are well enough to be up and about (able to do light activities or be in bed less than half the day).
- Your organs (like liver, kidneys, bone marrow) are working adequately.
- If you can become pregnant, you must have a negative pregnancy test before starting.
- You cannot have serious nerve damage (neuropathy), a history of lung inflammation, or active pneumonia.
- You must stop other cancer treatments, vaccines, or research studies at least 28 days before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
This trial tests combining two drugs (rituximab and tafasitamab) with donor natural killer (NK) cells to treat B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatments. The goal is to see if this combination can help the immune system fight the cancer more effectively.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
This trial tests a new drug, BMS-986458, alone or with other lymphoma treatments, for people with non-Hodgkin lymphoma that has come back or not gotten better after prior treatment.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.